US 11,993,661 B2
Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
Hong Liu, El Sobrante, CA (US); Hongruo Yun, San Francisco, CA (US); Xiaomei Ge, Foster City, CA (US); Zhiyuan Yang, Albany, CA (US); Lianxing Liu, San Francisco, CA (US); Pengbo Zhang, Fremont, CA (US); Yixiang Xu, Pearland, TX (US); Shan Li, Emeryville, CA (US); and Lucas Horan, Emeryville, CA (US)
Assigned to EUREKA THERAPEUTICS, INC., Emeryville, CA (US)
Appl. No. 17/253,589
Filed by EUREKA THERAPEUTICS, INC., Emeryville, CA (US)
PCT Filed Jun. 17, 2019, PCT No. PCT/US2019/037534
§ 371(c)(1), (2) Date Dec. 17, 2020,
PCT Pub. No. WO2019/245991, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/686,605, filed on Jun. 18, 2018.
Prior Publication US 2022/0185910 A1, Jun. 16, 2022
Int. Cl. C07K 16/00 (2006.01); A61P 35/00 (2006.01); C07H 21/04 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); C12N 5/02 (2006.01); C12N 15/00 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/3069 (2013.01) [A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/2809 (2013.01); G01N 33/57434 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)] 25 Claims
 
1. An anti-prostate specific membrane antigen (PSMA) construct comprising an anti-PSMA antibody moiety specifically recognizing an extracellular domain of PSMA comprising the amino acid sequence of SEQ ID NO: 44, wherein the anti-PSMA antibody moiety comprises:
a) a heavy chain variable domain (VH) comprising a heavy chain complementarity determining region (CDR-H) 1 comprising the amino acid sequence of SEQ ID NO: 1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 3, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 5; and a light chain variable domain (VL) comprising a light chain complementarity determining region (CDR-L) 1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR-L2 comprising the amino acid sequence GNS, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9; or
b) a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 2, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6; and a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 8, a CDR-L2 comprising the amino acid sequence SNN, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 10.